Hormone receptor negative HER2 positive breast cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:04 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hormone receptor negative HER2 positive breast cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Exercise Program Study for Early Breast Cancer Patients Taking Aromatase Inhibitors With or Without CDK4/6 Inhibitors to Improve Quality of Life https://clinicaltrials.eu/trial/exercise-program-study-for-early-breast-cancer-patients-taking-aromatase-inhibitors-with-or-without-cdk4-6-inhibitors-to-improve-quality-of-life/ Wed, 29 Apr 2026 15:08:38 +0000 https://clinicaltrials.eu/trial/exercise-program-study-for-early-breast-cancer-patients-taking-aromatase-inhibitors-with-or-without-cdk4-6-inhibitors-to-improve-quality-of-life/ This study involves patients with early breast cancer who are receiving specific hormone treatments. The disease being studied is hormone receptor positive and HER2 negative breast cancer that has been treated and shows no signs of remaining disease. The treatments used in this study include several types of hormone-blocking medications. These include anastrozole, which is given as a tablet by mouth, letrozole, also taken as a tablet, and exemestane, another tablet form medication. Some patients may also receive medications that suppress hormone production, such as goserelin, which is given as an implant injection into the muscle, or leuprorelin acetate, which is given as an injection that releases medication slowly over time. Additionally, some patients may be taking medications called CDK4/6 inhibitors, which include abemaciclib or ribociclib, both given as tablets. These CDK4/6 inhibitors help prevent cancer cells from growing and dividing.

The purpose of this study is to find out if a six-month exercise training program can improve the quality of life for patients who are taking these hormone treatments. Hormone treatments can cause various side effects that affect daily life, and exercise may help reduce these effects. The study will look at how exercise impacts symptoms related to the hormone treatment, overall quality of life, joint and muscle pain, tiredness, body composition including weight and muscle mass, sexual health, thinking abilities, and how well patients are able to continue taking their prescribed medications.

Patients who join the study will be randomly assigned to either participate in a supervised exercise program for six months or to continue with their usual activities. Those in the exercise group will work with exercise professionals and use a virtual training platform to help them follow the program. Throughout the study, all patients will continue taking their regular breast cancer medications as prescribed by their doctors. Patients will be asked to complete questionnaires at different times during the study to assess their quality of life, pain levels, and fatigue. They will also have measurements taken of their body composition and will have regular medical check-ups to monitor their health and any side effects from their cancer treatment. The study will track how well patients stick to both their exercise program and their cancer medications.

]]> Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy https://clinicaltrials.eu/trial/study-comparing-sacituzumab-govitecan-with-other-treatments-for-patients-with-hr-her2-metastatic-breast-cancer-after-endocrine-therapy/ Wed, 29 Apr 2026 14:23:29 +0000 https://clinicaltrials.eu/trial/study-comparing-sacituzumab-govitecan-with-other-treatments-for-patients-with-hr-her2-metastatic-breast-cancer-after-endocrine-therapy/ This clinical trial is focused on studying a type of breast cancer known as hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer. This type of cancer is characterized by the presence of hormone receptors and the absence of a protein called HER2. The study involves patients who have advanced or metastatic breast cancer, meaning the cancer has spread beyond the breast to other parts of the body, and who have already received treatment with hormone therapy.

The main treatment being studied is a medication called sacituzumab govitecan, which is also known by its code name IMMU-132. This medication is an antibody-drug conjugate, which means it combines an antibody with a drug to target cancer cells more precisely. The study will compare the effects of sacituzumab govitecan with other treatments chosen by the patient’s doctor, which may include medications like capecitabine, nab-paclitaxel, or paclitaxel. These are all types of chemotherapy drugs used to treat cancer.

The purpose of the study is to evaluate how well sacituzumab govitecan works compared to the other treatments in terms of delaying the progression of the disease. Patients participating in the study will receive either sacituzumab govitecan or one of the other treatments, and their health will be monitored over time to assess the effects of the treatment. The study will involve regular check-ups and assessments to track the progress of the cancer and any side effects of the treatments. The study aims to provide valuable information that could help improve treatment options for patients with this type of breast cancer in the future.

]]> Study on the Impact of Fluoroestradiol F-18 PET on Treatment for Patients with ER+ HER2- Metastatic Breast Cancer After First-Line Hormone Therapy Relapse https://clinicaltrials.eu/trial/study-on-the-impact-of-fluoroestradiol-f-18-pet-on-treatment-for-patients-with-er-her2-metastatic-breast-cancer-after-first-line-hormone-therapy-relapse/ Wed, 29 Apr 2026 14:22:44 +0000 https://clinicaltrials.eu/trial/study-on-the-impact-of-fluoroestradiol-f-18-pet-on-treatment-for-patients-with-er-her2-metastatic-breast-cancer-after-first-line-hormone-therapy-relapse/ This clinical trial is focused on studying the impact of a special imaging technique on the treatment of patients with a specific type of breast cancer. The disease being studied is metastatic breast cancer, which means the cancer has spread to other parts of the body. The patients involved in this study have breast cancer that is estrogen receptor-positive (ER+) and HER2-negative. This means their cancer cells grow in response to the hormone estrogen but do not have an excess of the HER2 protein. The patients have experienced a return of cancer after their initial treatment, which included hormone therapy.

The treatment being tested in this study is called FLUOROESTRADIOL F-18, also known by the code name EstroTep. This is a solution that is injected into the body and used in a type of imaging called Positron Emission Tomography (PET). The purpose of the study is to see how this imaging technique can help doctors make better treatment decisions for patients whose cancer has returned after the first line of treatment. The study will involve patients undergoing a PET scan with FLUOROESTRADIOL F-18 to help guide their future treatment options.

Throughout the study, patients will receive the PET scan and their doctors will use the results to decide on the best course of treatment. This may involve changes to their current treatment plan, such as adjusting hormone therapy or adding other treatments like chemotherapy or radiotherapy. The study aims to understand how this imaging technique can improve the management of metastatic breast cancer and help doctors make more informed decisions about patient care.

]]>